trending Market Intelligence /marketintelligence/en/news-insights/trending/uTB_dx4np6r5oonuMXuP3g2 content esgSubNav
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us
In This List

Momenta Pharmaceuticals upsizes offering to raise up to $258.7M

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


Momenta Pharmaceuticals upsizes offering to raise up to $258.7M

Momenta Pharmaceuticals Inc. priced a common stock offering to raise about $225 million in gross proceeds.

The Cambridge, Mass.-based biotechnology company is selling 14,516,130 common shares at $15.50 apiece. Momenta has also granted underwriters a 30-day option to buy 2,177,419 additional shares for additional proceeds of about $33.7 million.

Goldman Sachs & Co. LLC and J.P. Morgan are joint lead book-running managers, while Stifel is a book-running manager for the offering.